Last quarter (Q4 2023), Pliant Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q4, Pliant Therapeutics's net income was $-41.11M. See Pliant Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 1.58M	$ 1.58M	$ 9.69M	$ 7.57M	$ 41.82M	$ 57.05M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 1.58M	$ 1.58M	$ 9.69M	$ 7.57M	-	-
Operating Expense	$ 185.72M	$ 185.72M	$ -136.88M	$ -105.11M	$ 83.46M	$ 58.28M
Operating Income	$ -184.15M	$ -184.15M	$ -127.20M	$ -97.53M	$ -41.65M	$ -1.23M
Net Non Operating Interest Income Expense	$ -640.00K	$ -1.27M	-	-	$ 112.00K	$ 816.00K
Other Income Expense	-	-	-	$ -202.00K	$ -366.00K	$ -216.00K
Pretax Income	$ -184.78M	$ -185.41M	$ -127.20M	$ -97.53M	$ -41.53M	$ -631.00K
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -160.71M	$ -161.34M	$ -123.32M	$ -97.26M	$ -41.53M	$ -13.08M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 185.72M	$ 185.72M	$ -136.88M	$ -105.11M	$ 83.46M	$ 58.28M
Net Income From Continuing And Discontinued Operation	$ -161.34M	$ -161.34M	$ -123.32M	$ -97.26M	$ -41.53M	$ -631.00K
Normalized Income	$ -75.33M	$ -146.48M	-	-	$ -41.53M	$ -631.00K
Interest Expense	-	-	-	-	-	-
EBIT	$ -183.52M	$ -184.15M	$ -127.20M	$ -97.53M	$ -41.65M	$ -1.23M
EBITDA	$ -134.03M	$ -184.94M	$ -125.35M	$ -94.37M	$ -40.34M	$ -118.00K

Currency in USD

Pliant Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing